

RESEARCH ARTICLE

Open Access



IL-10R α expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma

Isabella Venza^{1†}, Maria Visalli^{1†}, Concetta Beninati^{2,3}, Salvatore Benfatto², Diana Teti¹ and Mario Venza^{1*}

Abstract

Background: IL-10 is an immunoregulatory cytokine that increases during malignant diseases. The purpose of this study was to: i) determine the mRNA amounts of *IL-10*, *IL-10R α* , and *IL-10R β* in cutaneous and uveal melanoma cells and specimens; ii) evaluate their post-transcriptional regulation by miRNAs; iii) ascertain whether miRNA dysregulation may affect IL-10-induced proliferation.

Methods: Genome-wide miRNA expression profiling was performed using a human microarray platform. The reference gene mRNA was measured through qPCR. miRNAs/mRNAs interactions were predicted by TargetScan, microRNA, and PITA. Transfections of specific miRNA mimics/inhibitors were carried out. Cell proliferation was assessed by MTT assay in the presence of IL-10 after transfection with miRNA mimics/inhibitors.

Results: There were no differences in IL-10 mRNA levels between any of the 3 melanoma cell lines tested and normal melanocytes. However, lower *IL-10R α* expression was found in G361 and OCM-1 cells, and higher levels of *IL-10R β* were observed in G361 cells compared with normal melanocytes. GR-M cells did not exhibit any modifications in *IL-10R α* and *IL-10R β* expression. miR-15a, miR-185, miR-211, and miR-30d were upregulated in G361 and OCM-1 cells, remaining at similar levels in GR-M cells. miR-409-3p and miR-605 were down-regulated exclusively in G361 cells. Prediction tools revealed that miR-15a, miR-185, and miR-211 targeted *IL-10R α* whereas none of the miRNAs exclusively downregulated in G361 cells targeted *IL-10R β* . Luciferase reporter and western blot assays showed that *IL-10R α* expression is directly regulated by miR-15a, miR-185, and miR-211, either alone or in combination. An inverse expression pattern between *IL-10R α* , on one side, and miR-15a, miR-185, and miR-211 on the other one was also shown in melanoma samples. Ectopic expression of individual miR-15a, miR-185, and miR-211, and even more their co-expression, caused a marked decrease in the proliferation rate of all the cell lines. Likewise, inhibition of any specific miRNA promoted cell growth, an effect that further increased when inhibition concerned all three miRNA. Moreover, specific knockdown of IL-10R α prevented the proliferative effect of miRNA inhibitors.

Conclusions: Our results support a key role of *IL-10R α* in the development and progression of melanoma and suggest that the IL-10/IL-10 receptor system may become a new therapeutic target for melanoma treatment.

Keywords: IL-10, IL-10R α , IL-10R β , miRNAs, Cutaneous melanoma, Uveal melanoma

* Correspondence: mariovenza@gmail.com

[†]Equal contributors

¹Department of Clinical and Experimental Medicine, Azienda Policlinico Universitario G. Martino, via Consolare Valeria, 1, Messina 98125, Italy
Full list of author information is available at the end of the article

Background

IL-10 is generally believed to repress the inflammatory response [1] and immune reactions against a variety of tumors [2, 3]. This cytokine is secreted by immune and non-immune cells [4] and its production was found to increase during malignant diseases, including melanoma [5].

The ability of IL-10 to affect melanoma growth under a variety of conditions renders this cytokine an interesting topic of research in this field, although the mechanisms involved are complex and incompletely understood [6–8]. Some studies suggested that high local levels of this cytokine may favor melanoma growth by suppressing the activities of tumor-infiltrating cells involved in anti-tumor immunity. For example, it was shown that IL-10 can decrease proinflammatory cytokine expression [9] or anti-tumor T cell responses [7, 9]. These data suggested that the production of IL-10 by melanoma cells and its release in the surrounding microenvironment might produce a paralysis of the anti-melanoma immune response [5].

In contrast, other studies indicate that IL-10 may augment the effects of anti-melanoma vaccination [10] or inhibit melanoma metastasis through activation of NK cells [6]. Moreover, it was reported that IL-10 repressed tumor growth and the metastatic potential of melanoma cells by inhibiting the expression of angiogenic factors and, thereby, vascularization [8]. Irrespectively of the effects of IL-10 on the immune response, the direct effects of this cytokine on melanoma cell themselves have been only incompletely addressed, although one study suggested that IL-10 might function as an autocrine growth factor [7].

Expression of the IL-10R on the cell surface is absolutely required for the responsiveness to this cytokine, but its role is in the context of melanoma development is ill-understood. IL-10R is composed of two different chains (IL-10R α and IL-10R β). The alpha chain binds directly to IL-10 and the beta chain is subsequently recruited into the IL-10/IL-10R α complex. Although it is generally believed that signal transduction pathways are triggered only after binding of the beta chain, it cannot be ruled out that this occurs also during initial binding of IL-10 to IL-10R α [4].

Emerging evidence suggests a role for epigenetic modulation in melanomagenesis. In particular, miRNAs have been recognized as important mediators of biological processes linked to melanoma, including growth, cell cycle, invasiveness, migration, and immune evasion [11]. Given that very few data are available about the post-transcriptional regulation of the IL-10 system and its role in melanoma cell behavior, we aimed at investigating the involvement of miRNAs in the expression levels of IL-10 and its receptors in cutaneous and uveal melanoma cells.

Methods

Cell cultures

G361 cutaneous melanoma cells (ECACC, European Collection of Cell Cultures, Salisbury, UK) were grown in McCoy's 5a medium modified with 10 % FBS, 2 mM L-glutamine, and 1 % penicillin/streptomycin. The cutaneous melanoma cell line GR-M (ECACC, European Collection of Cell Cultures, Salisbury, UK) and the uveal melanoma cell line OCM-1 (provided by J. Mellon, Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX) were cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 1 % penicillin/streptomycin, and 10 % FBS.

Tumor specimens

To exclude that our observations were restricted to cell lines maintained in long-term culture, we also examined primary tumors. Formalin-fixed paraffin-embedded (FFPE) tissue sections of 52 cutaneous melanomas (31 females and 21 males, age ranging from 45 to 65 years), 41 uveal melanomas (15 females and 26 males, age ranging from 52 to 68 years), and 35 normal skin specimens, taken from patients of the University Hospital of Messina, were examined. The investigation adhered to the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital of Messina. An informed verbal consent was given by patients.

Total RNA extraction, reverse transcription and qPCR

Total RNA was extracted by TRIzol Reagent (Invitrogen). RNA samples were quantified with a Nanodrop 1000 spectrophotometer and their quality was evaluated using Agilent RNA 6000 Nano Assay. RNA samples were converted into cDNA using IMProm-II™ reverse transcriptase kit (Promega). Quantitative Real-Time PCR was performed by ABI Prism 7500 Real-Time PCR System (Applied Biosystems, Milan, Italy) with SYBR Green Mastermix (Applied Biosystems, UK). Primers were previously reported [12, 13]. The mRNA levels of *IL-10*, *IL-10R α* , and *IL-10R β* were normalized to endogenous β -actin (Applied Biosystems).

miRNA microarray

miRNA microarray experiments were performed using a human miRNA microarray platform (Agilent Sanger miRBase, release 10.1) with 723 human and 76 human viral miRNAs represented. Agilent Feature Extraction Software was used for background subtraction. LOWESS and Quantile normalizations were performed.

Oligonucleotide transfection

MiR-15a, miR-185, and miR-211 mimics/inhibitors (Qiagen, Milan, Italy) were transfected either alone or in combination into melanoma cells using HiPerFect

according to the manufacturer's protocols (Qiagen). Cells were transfected twice with 100 pmol of oligonucleotide per well (0.5×10^6 cells) at 24 h intervals. Transfected cells were assayed 48 h after the second transfection.

Western blot analysis

Total cell extracts (50 μ g) were resolved by SDS-PAGE and blotted onto nitrocellulose membranes with specific antibodies against IL-10 (sc-8438, Santa Cruz Biotechnology), IL-10R α (sc-984, Santa Cruz Biotechnology), and IL-10R β (sc-514822, Santa Cruz Biotechnology).

Plasmids constructs and transient transfections

The 3'-UTR of IL-10R α and a mutation sequence were amplified by PCR using the primers with a Bgl II restriction site on each 5' or 3' strand. The PCR products were inserted into the Bgl II sites of the pGL3-control vector (Promega, Madison, WI, USA) and identified by DNA sequencing. The wild-type plasmids were created containing the 3'-UTR of IL-10R α with complementary sequence of miR-15a (IL-10R α 3'-UTR wild 1), miR-185 (IL-10R α 3'-UTR wild 2), miR-211 (IL-10R α 3'-UTR wild 3) or covering all the three miRNA side sites (IL-10R α 3'-UTR wild-full-length). Four mutant plasmids were generated with the mutation sequence without complementary sequence of miR-15a (pGL3-IGF-1 3'-UTR mut 1), miR-185 (pGL3-IGF-1 3'-UTR mut 2), and miR-211 (pGL3-IGF-1 3'-UTR mut 3) or all of them (IL-10R α 3'-UTR mut-full-length). For the luciferase reporter assay, cells were seeded on 24-well plates and co-transfected using Lipofectamine 2000 (Invitrogen) with 100 ng per well of the resulting luciferase UTR-report vector, 2 ng per well of pRLCMV vector (internal control, Promega), and 20 ng per well of miR-15a, miR-185, and miR-211 mimics or inhibitors following the manufacturer's instructions (Qiagen, Milan, Italy). After 24 h, the cells were lysed, and the relative luciferase activity was assessed with the Dual-Luciferase Assay Reporter System (Promega). For transient knockdown of IL-10R α , cells were transfected with specific small interfering RNA (siRNA) targeting IL-10R α or non-targeting control siRNA (Santa Cruz Biotechnology, Milan, Italy) 24 h after plating using Lipofectamine 2000 (Invitrogen) with the siRNA at a final concentration of 100 nM.

Cell proliferation assay

Cells were treated with recombinant human IL-10 (R & D Systems) at various doses (50, 100, or 500 U/ml) and for different times (at 6-hr intervals during a 72-hr culture period) accordingly to previously reported conditions [7]. Proliferation was measured using the MTT Assay Kit (Cayman Chemical Company, Michigan, USA).

Densitometry and statistical analysis

The one-way analysis of variance (ANOVA) test, followed by a pair-wise multiple comparison test (Bonferroni t test), was performed to identify the differences among the groups. The relative intensities of protein bands were analyzed by Image J software (Bethesda, MD, USA). Statistical significance was assigned when the p value was <0.05.

Results

Expression levels of IL-10, IL-10R α , and IL-10R β in cutaneous and uveal melanoma cells

The mRNA content of IL-10 and its receptor subunits (IL-10R α and IL-10R β) was analyzed by quantitative PCR (qPCR) in two cutaneous (G361 and GR-M) and one uveal (OCM-1) melanoma cell lines and compared to that of NHEM. As shown in Fig. 1, levels of IL-10 mRNA expression did not significantly differ from that of NHEM in any of the cell lines examined. Lower amounts of IL-10R α expression were found in G361 and OCM-1 cells, and higher levels of IL-10R β were observed in G361 cells. GR-M did not exhibit any modifications in IL-10R α or IL-10R β expression.


Prediction of miRNAs targeting IL-10R α and IL-10R β

To test for possible post-transcriptional modulation of IL-10R α and IL-10R β expression by miRNAs, genome-wide miRNA expression profiling was carried out. Figure 2 (sections B and C) shows that, as compared to NHEM, only 4 miRNAs (miR-15a, miR-185, miR-211, and miR-30d) were upregulated in G361 and OCM-1 cells, while remaining at similar levels in GR-M cells. Two miRNAs (miR-513a-5p and miR-551b) were down-regulated exclusively in G361 cells. The expression levels of these miRNAs were confirmed by qPCR (*data not shown*).

To predict miRNAs/mRNAs interactions, TargetScan (<http://www.targetscan.org/>), microRNA (www.microna.org/) and PITA (http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html) were used. Three out of the four miRNAs upregulated in G361 and OCM-1 and unchanged in GR-M were predicted to have seed regions able to bind to the 3'UTR of IL-10R α (miR-15a was reported in all the miRNA target prediction systems, miR-185 in microRNA and PITA; miR-211 in microRNA and PITA). None of the miRNAs exclusively downregulated in G361 cells had IL-10R β as a putative target transcript.

IL-10R α is a target of miR15a, miR185, and miR211

To validate the direct interaction of miR15a, miR185, and miR211 with IL-10R α mRNA (Fig. 3a), we constructed a luciferase reporter system containing a binding site (IL-10R α -3'-UTR-wt) or a mutated site (IL-10R α -3'-UTR-mut). The vectors were co-transfected into G361, GR-M, and OCM-1 cells with miR15a, miR185, and miR211 mimics or inhibitors. The luciferase activity of IL-10R α -



3'-UTR-wt in cells transfected with miR-15a, or miR-185, or miR-211 mimics was significantly decreased ($p < 0.001$), compared to negative controls. When the three mimics were co-transfected, luciferase activity was almost abolished. However, none of them, either alone or in

combination, affected the transcription of the pGL3-IL-10R α -mut vector (Fig. 3b). When blocking the expression of the three miRNAs with specific inhibitors, luciferase intensity markedly increased in cells transfected with the IL-10R α -3'-UTR-wt vector ($p < 0.001$). This increase was higher when cells were co-transfected with all the three inhibitors. No change in cells transfected with pGL3-IL-10R α -mut (Fig. 3c) was observed. These results suggest that the 3'-UTR of *IL-10R α* mRNA might be the target of miR15a, miR185, and miR211. Next, we further investigated the regulation of *IL-10R α* protein expression by miR-15a, miR-185, and miR-211. Western blot showed that the IL-10R α expression significantly decreased in cells transfected with individual mimics and was almost abolished by their combination. IL-10 and IL-10R β were not affected by any of the miRNA mimics either alone or in combination (Fig. 3d).

The IL-10/IL-10R system and miR-15a, miR-185, miR-211 expression in cutaneous and uveal melanoma samples

Next, we proceeded to explore the expression of the members of IL-10/IL-10R system, miR-15a, miR-185, and miR-211 in cutaneous and uveal melanoma samples as compared to normal skin. Figure 4 shows significant higher levels of IL-10R α (section A) accompanied by a correspondent decrease in miR-15a, miR-185, and miR-211 (section B) in tumor specimens. IL-10 and IL-10R β did not show significant modification in their expression levels (section A).

Effects of miR-15a, miR-185, and miR-211 on IL-10-induced melanoma cell proliferation

As the melanoma environment is characterized by high levels of IL-10 [14], we analyzed the effects of miR-15a, miR-185, and miR-211 on the growth of melanoma cells exposed to this cytokine. Firstly, cells were cultured in presence of various doses of IL-10 (50, 100, or 500 U/ml), and the proliferation was determined at 6-hr intervals during a 72-hr culture period. As seen in Fig. 5a, relative to cells with medium alone, the proliferation of GR-M cells dramatically increased during the 12–48 h interval following treatment with IL-10 at concentrations ranging from 100 through 500 U/ml. G361 and OCM-1 cells showed a slight, non-significant increase in cell growth after exposure to IL-10. These data show that IL-10 was able to induce optimal proliferative effects in GR-M cells already at a concentration of 100 U/ml in agreement with previous studies using T cells [15] and that this increase was also observed at 500 U/ml. Therefore, treatment with 100 U/ml of IL-10 for 36-hr was used for cell proliferation assays in the presence of miR-15a, miR-185, and miR-211 mimics or inhibitors. Proliferation was reduced after transfection of all the cell lines with individual miRNA mimics and almost abolished following co-




Fig. 2 miRNA expression profiles in cutaneous and uveal melanoma. **a** Venn diagram illustrating the common and specific miRNAs in the indicated cells. **b** Heat map comparing the average fold-changes in microRNAs with significantly higher (red) or lower (green) expression in melanoma cells in comparison to normal human epidermal melanocytes (NHEM) (FDR ≤ 0.001). **c** Heat map relative to the 4 common miRNAs with up-regulated expression pattern in OCM-1 and G361 cells and the 2 common miRNAs down-regulated exclusively in OCM-1. FDR, false discovery rate

transfection with the combined mimics (Fig. 5b). Knock-down of miR-15a, or miR-185, or miR-211 markedly promoted the proliferation in all the cell lines and the combined inhibitors further increased growth. The proliferative effects of miRNA inhibitors, either alone or in combination, were abolished when IL-10Rα was silenced by the specific siRNA (Fig. 5c).

Discussion

IL-10 has been extensively studied for its ability to affect immune responses against a wide variety of cancers, and, to a lesser extent, also against the melanoma [4]. Regarding this tumor, conflicting findings are reported, some of which showing that IL-10 significantly contributes to melanoma development [7, 9], and some others indicating that this cytokine strengthens the effects of

anti-melanoma vaccines and NK cells [6, 10]. Moreover, what are the direct effects of IL-10 on melanoma cells and whether the latter differ from normal melanocytes in their responsiveness to the cytokine is presently unclear. Here we did not observe any significant changes in *IL-10* expression in the melanoma cell lines studied relative to normal melanocytes (Fig. 1). However, literature data are contradictory in this regard, as some papers report that IL-10 is an autocrine melanoma growth factor [7, 16], others obtained uneven results in their melanoma cell systems [5], and still others found that IL-10, as well as its receptor, are expressed at lower levels in melanoma samples than in healthy skin [14]. In this context, a more prominent role seemed to be played by *IL-10Rα* expression than by IL-10 production, according to our data (Fig. 1). Indeed, the uveal and cutaneous melanoma





Fig. 4 IL-10/IL-10R system and miR-15a, miR-185, miR-211 expression in cutaneous and uveal melanoma samples. Total RNA was extracted from 35 normal skin specimens, 52 cutaneous melanomas, and 41 uveal melanomas, reverse-transcribed, and analyzed by qPCR to determine the relative amounts of IL-10, IL-10Rα, IL-10Rβ mRNA (a) and miR-15a, miR-185, miR-211 (b). Data are representative of three independent experiments. Means of the measurements are shown with black lines

critical gap in the understanding of the role of the IL-10/IL-10R system in melanoma, since α and β chains are encoded by distinct genes and display different role in triggering the signaling events [4]. In this regard, here we showed that the expression of *IL-10Rα* is crucial for the melanoma cell responsiveness to IL-10.

Melanocytes play a central role in skin innate immune system and inflammation [20] to the point that they have been defined “a sensitive barometer of inflammatory conditions of the skin” [21]. The recently evidenced role of miRNA dysregulation in melanoma [11, 22], prompted us to investigate whether differential expression of the two chains of IL-10R occurring in the three different melanoma models was in association with specific miRNA profiles. We found that as many as three out of four miRNAs (namely miR-15a, miR-185, and miR-211) were increased in cells with low expression of IL-10Rα, and that these regulatory molecules targeted the *IL-10Rα* gene (Fig. 2). This conclusion stemmed from a series of experiments based on miRNA target

prediction tools, miRNA target reporter assay, and western blot (Fig. 3). The amounts of IL-10 and IL-10Rβ proteins were not affected by the three miRNAs. The expression profile of IL-10/IL-10R, miR-15a, miR-185, and miR-211 observed in cutaneous and uveal melanoma tissues exhibited the same trend observed in melanoma cell lines (Fig. 4). Interestingly, miR-15a, miR-185, and miR-211 are thought to function as tumor suppressors in melanocytes, as they repress many genes implicated in the melanomagenesis. For example, downregulation of miR-15a, which is observed in several cancers including melanoma, led to an overexpression of several oncogenes, such as *Bcl-2*, *Cyclin D1*, and *Mcl-1* [23]. In addition, miR-185 exhibits strong anti-proliferative effects on melanoma either *in-vitro* or *in vivo* [24] and miR-211 inhibits the aggressive and invasive phenotype of melanoma cells [11]. However, to our knowledge, the regulation of *IL-10Rα* expression by these three miRNAs and the possible significance of *IL-10Rα* downregulation in melanoma cell proliferation have not yet been addressed. Here we



showed that miR-15a, miR-185, and miR-211 mimics inhibited and miRNA inhibitors increased the proliferation of IL-10-treated melanoma cells through IL-10 signaling, since the silencing of *IL-10R α* cancelled the effects of miRNA inhibitors on the proliferation (Fig. 5). Another interesting finding from these experiments is that the three miRNAs considered exerted synergistic effects both in modulating the expression of *IL-10R α* or in regulating the proliferation of melanoma cells. These data suggest the potential usefulness of a combined therapeutic strategy targeted to the expression of miR-15a, miR-185, and miR-211 in melanoma cells.

Data presented here acquire perhaps further relevance in light of a recent paper showing that the expression of IL-10 and IL-10R, despite the great variability, is lower in melanomas compared to normal skin [14]. In this context, our findings give emphasis to whether or not

melanoma cells express *IL-10R α* , as the expressing cells proliferated in the presence of IL-10 – which may be produced by melanoma environment – while the non-expressing melanoma cells were unresponsive to the cytokine. Therefore, our data add to our knowledge about the significance of *IL-10R α* post-transcriptional regulation in the characteristics of malignancy of melanoma, independently from the questioned immunostimulant or immunosuppressive role of IL-10.

Conclusions

Taken together, findings reported in the present study suggest that the *IL-10R α* expression in melanoma cells is post-transcriptionally regulated by miR-15a, miR-185, and miR-211. The variability in *IL-10R α* mRNA amounts we observed is correlated with the differences in cell growth in response to IL-10. Thus, it could be argued

the IL-10/IL-10 receptor system may become a new epigenetic therapeutic target for melanoma treatment.

Availability of supporting data

All microarray data of this paper have been deposited in the LabArchives, LLC (<http://www.labarchives.com/>), under doi :10.6070/H4C53HWK.

Abbreviations

Interleukin10: IL-10; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; IL-10 receptor: IL-10R; miRNAs: microRNAs; qPCR: Quantitative PCR; Bcl-2: B-cell CLL/lymphoma 2; Mcl-1: Myeloid cell leukemia 1.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MVe, MVI, and IV conceived the study design, performed the experiments, participated in the data analysis/interpretation and wrote the manuscript. CB and SB contributed to data analysis/interpretation. DT has conceptualization of idea, provided directions for the work, and contributed to manuscript preparation and editing. All authors read related literatures, joined regular discussion and solved experimental problems. All authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge the critical review by Professor Giuseppe Teti. Work described here was supported in part by funds granted to Scylla Biotech Srl by the Ministero dell'Università e della Ricerca Scientifica of Italy (Project n.4/13 ex art. 11 D.M. n. 593).

Author details

¹Department of Clinical and Experimental Medicine, Azienda Policlinico Universitario G. Martino, via Consolare Valeria, 1, Messina 98125, Italy. ²Department of Human Pathology of Adult and Developmental Age "Gaetano Barresi", Azienda Policlinico Universitario G. Martino, via Consolare Valeria, 1, Messina 98125, Italy. ³Scylla Biotech Srl, University of Messina, Messina, Italy.

Received: 3 September 2015 Accepted: 18 November 2015

Published online: 03 December 2015

References

- Trifunović J, Miller L, Debeljak Ž, Horvat V. Pathologic patterns of interleukin 10 expression—a review. *Biochem Med (Zagreb)*. 2015;25:36–48.
- Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. *Cancer Res*. 2006;66:5527–36.
- Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. *J Leukoc Biol*. 2005;78:1043–51.
- Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy—review of a new approach. *Pharmacol Rev*. 2003;55:241–69.
- Krüger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankenstein T, et al. Expression of interleukin 10 in human melanoma. *Br J Cancer*. 1994;70:1182–5.
- Gérard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M, et al. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. *Hum Gene Ther*. 1996;7:23–31.
- Yue FY, Dummer R, Geertsens R, Hofbauer G, Laine E, Manolio S, et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. *Int J Cancer*. 1997;71:630–7.
- Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. *Clin Cancer Res*. 1996;2:1969–79.
- Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. *Int J Cancer*. 1994;56:755–60.
- Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. *Blood*. 2001;98:2143–51.
- Aftab MN, Dinger ME, Perera RJ. The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma. *Arch Biochem Biophys*. 2014;563:60–70.
- Bolpetti A, Silva JS, Villa LL, Lepique AP. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. *BMC Immunol*. 2010;11:27.
- Srisodsai A, Kurotani R, Chiba Y, Sheikh F, Young HA, Donnelly RP, et al. Interleukin-10 induces uteroglobin-related protein (UGRP) 1 gene expression in lung epithelial cells through homeodomain transcription factor T/EBP/NKX2.1. *J Biol Chem*. 2004;279:54358–68.
- Wiguna AP, Walden P. Role of IL-10 and TGF-β in melanoma. *Exp Dermatol*. 2015;24:209–14.
- Rowbottom AW, Lepper MA, Garland RJ, Cox CV, Corley EG. Interleukin-10-induced CD8 cell proliferation. *Immunology*. 1999;98:80–9.
- Lázár-Molnár E, Hegyesi H, Tóth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. *Cytokine*. 2000;12:547–54.
- Reiche J, Pauli G, Ellerbrok H. Differential expression of human endogenous retrovirus K transcripts in primary human melanocytes and melanoma cell lines after UV irradiation. *Melanoma Res*. 2010;20:435–40.
- Chartrain M, Riond J, Stenvein A, Van den Berghe I, Gomes B, Lamant L, et al. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. *PLoS One*. 2012;7:e36762.
- Venza M, Visalli M, Catalano T, Fortunato C, Oteri R, Teti D, et al. Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. *Biochem Biophys Res Commun*. 2013;441:743–50.
- LePoole IC, Van Den Wungaard RM, Westerhof W, Verkruisen RP, Dutrieux RP, Dingemans KP, et al. Phagocytosis by normal human melanocytes in vitro. *Exp Cell Res*. 1993;205:388–95.
- Papa CM, Kligman AM. The behavior of melanocytes in inflammation. *J Invest Dermatol*. 1965;45:465–74.
- Venza M, Dell'Aversana C, Visalli M, Altucci L, Teti D, Venza I. Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines. *Tumori*. 2014;100:e4–7.
- Pekarsky Y, Croce CM. Role of miR-15/16 in CLL. *Cell Death Differ*. 2015;22:6–11.
- Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. *PLoS One*. 2011;6:e18936.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

